A new day in preventing meningococcal disease: Sizing up the available vaccines
The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Recent Videos
Related Content
